Galaxy Hooks Roche for Preclinical Oncology Program
By Marie Powers
Tuesday, September 25, 2012
Galaxy Biotech LLC jumped back into the big fish pond, inking exclusive worldwide development and commercialization rights to a humanized monoclonal antibody (mAb) targeting fibroblast growth factor 2 (FGF2) in cancer to Roche AG.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.